Everyone in tech agrees we’re in a bubble. They just can’t agree on what it looks like — or what happens when it pops. MIT Technology Review Explains: Let our writers untangle the complex, messy world ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Big Tech’s huge investment in artificial intelligence is making investors nervous. But the technology continues to advance, buoying the bulls. By Brian O’Keefe Jensen Huang, C.E.O. of Nvidia, has seen ...

After years of explosive growth, experts are now pointing to potential cracks in AI’s foundation. Astronomical industry valuations, vast levels of investment and a promise of exponential progress have ...

The market seems to be content, for now at least, to keep betting big on AI. While the value of some companies integral to the AI boom like Nvidia, Oracle and Coreweave have seen their value fall ...

OpenAI CEO Sam Altman's comments helped spark concerns about an AI bubble. Mark Cuban says he doesn't see similarities to the dot-com bubble. There's disagreement, even among business leaders and tech ...

Andrew Beattie was part of the original editorial team at Investopedia and has spent twenty years writing on a diverse range of financial topics including business, investing, personal finance, and ...

“We’re in the phase of the cycle where the rubber meets the road,” said Jim Morrow, chief executive officer of Callodine Capital Management. “It’s been a good story, but we’re sort of anteing up at ...